MD-PREVAILION
19.10.2020 13:02:07 CEST | Business Wire | Press release
Prevailion, a global leader in cyber adversary intelligence, today announced that it has been recognized as a Gartner Cool Vendor in the latest Cool Vendors in Security Operations and Threat Intelligence report.
The Gartner report profiles “emerging vendors that security and risk management leaders should consider when evaluating emerging threats requiring the latest in security operations technologies.” Gartner writes that: “Security and risk management leaders are seeking solutions for better visibility into their IT environments to help strengthen their security posture, as well as prioritize security control gaps and remediation activities based on business risk.” It also notes that: “Organizations struggle to mitigate vulnerabilities because of the inability to prioritize them due to a lack of context about the assets and external threat environment.”*
This lack of visibility into active and emerging threats poses a major challenge to organizational cybersecurity, and is the primary focus of Prevailion. Through a global constellation of clandestine sensors, Prevailion actively monitors thousands of cyber attacks in real-time, including billions of malware communications, providing an unprecedented level of adversary intelligence that companies can use to protect their networks.
“We are honored to be selected by Gartner, which we believe validates the core technology behind our platform and the hard work and dedication of our team,” said Karim Hijazi, founder and CEO of Prevailion. “At Prevailion, we have been charting a new course in the field of threat intelligence, by empowering companies with greater visibility into the threat actors targeting their networks and the networks of their closest partners. By going after the attackers’ own infrastructure, we can provide companies with unprecedented insights into criminal and nation-state hackers’ malicious activity and list of targets. This enables corporate security teams to better prioritize threats, by focusing immediately on confirmed attacks, rather than having to rely on noisy and error-prone security alerts or vague risk scorecards.”
EXCLUSIVE INSIGHTS INTO CYBER THREAT ACTIVITY
Prevailion is currently tracking over 28,000 compromised organizations around the world, ranging from publicly traded companies and their supply chain partners to governments, universities, NGOs and more. Many of the cyber compromises Prevailion has observed are undetected or unreported by the victim organizations.
According to Prevailion’s exclusive intelligence, 22% of the Fortune 500 are showing active or recent compromise activity by criminal or state-affiliated hackers. This includes 79% of software companies and 64% of pharmaceuticals, which are the most heavily targeted industries, based on recent cyber activity.
Prevailion’s unique cyber intelligence capability allows it to detect active compromises inside corporate networks that do not require any access or confirmation by the affected corporation. To do this, Prevailion’s intelligence team targets criminal networks in order to intercept communications between the hackers’ “command-and-control” servers and the malware they’ve deployed. This ability to eavesdrop on criminal activity gives Prevailion significantly enhanced insights into real-time hacking operations taking place all over the world. It also allows them to anticipate new attacks ahead of time.
Prevailion’s APEX Platform is a reliable source of information on thousands of unreported corporate breaches, and provides around-the-clock intelligence on new compromises, escalating breach activity and corporate remediation efforts.
*Gartner “Cool Vendors in Security Operations and Threat Intelligence,” Mitchell Schneider, Ruggero Contu, John Watts, Craig Lawson, October 13, 2020.
GARTNER DISCLAIMER
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
ABOUT PREVAILION
Prevailion is a compromise intelligence company, transforming the way organizations approach risk mitigation and business decision-making. Through next-level tailored intelligence and a zero-touch platform, Prevailion provides a full view of confirmed “Evidence of Compromise” (EOC) for customers and their partner ecosystems. To learn more about Prevailion, visit www.prevailion.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201019005166/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
